What this Ipamorelin review is — and what it is not.

An editorial reading, not a clinic

Reviews Ipamorelin is a long-form reading of the peer-reviewed research on ipamorelin, led through the molecule's gut and appetite biology. It runs no clinic and employs no clinicians. It offers no medical advice. It makes, sells, and ships nothing. The writing is commentary on published science, and every quantitative claim is cited.

The word "reviews" in the name means exactly one thing: what gets reviewed is the published evidence. Vendors, products, and sellers are not reviewed, and nothing here endorses any supplier. When a finding is called "reviewed," it means it has been read against its source study and weighed for what it does and does not support.

Why we lead with the gut

Most writing about ipamorelin leads with growth hormone and muscle. We lead with the gut and appetite, because that is where the molecule's biology is most revealing. Ipamorelin acts on the ghrelin receptor — the same receptor the body's hunger hormone uses — and that receptor sits in the stomach and the brain's appetite centers as much as in the pituitary. Reading ipamorelin through motility and hunger surfaces both its strongest mechanistic rationale and its most honest limitation: a clinically advanced drug class, and a single ipamorelin trial that did not succeed.

We weigh evidence rather than promote it. Where the data are strong — selectivity, pharmacokinetics — we say so plainly. Where they are thin, negative, or absent, we say that too. The failed Phase 2 trial is not buried here; it is central.

How we handle the evidence

Every quantitative claim is tied to a numbered citation with a DOI, PMID, or trial identifier. What controlled human trials show, what animal and cell studies show, and what research-use communities report are kept carefully apart — community reports are labeled anecdotal, never findings. Doses are described only as they appear in published studies, in the third person, and no human dosing recommendation is ever made. Ipamorelin is not approved for human use by any regulatory authority, and it is treated strictly as a subject of research.